Search company, investor...

Fermentas International

Founded Year



Acquired | Acquired



About Fermentas International

Fermentas is a leader in the discovery, manufacturing, and marketing of molecular biology products for scientific research in molecular biology and gene engineering laboratories.In July 2010, Fermentas International was acquired by Thermo Fisher Scientific. The valuation of Fermentas International was $260 million. Other terms of the deal were not released.

Headquarters Location

830 Harrington Court

Burlington, Ontario, L7N 3N4,


Missing: Fermentas International's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Fermentas International's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Latest Fermentas International News

Thermo Fisher Scientific to purchase Fermentas International

Apr 18, 2013

1 June 2010 Scientific Thermo Fisher Scientific is to acquire molecular and cellular biology research company Fermentas International in a transaction valued at $260 million (179.5 million pounds). The deal, which is expected to close during the third quarter of 2010 provided that regulatory approval is granted, will see Fermentas become part of Thermo Fisher's analytical technologies business unit. ““ Fermentas manufactures and distributes a range of enzymes, reagents and kits, including compounds for nucleic-acid and protein purification and molecular weight markers. Marc Casper, president and chief executive officer of Thermo Fisher Scientific, expressed confidence that the takeover will allow the science company to expand its polymerase chain reaction market presence. He added: "With Fermentas, we are better positioned to meet the demands of molecular and cell biologists for complete workflows that can accelerate their research and improve results. " Last month, Thermo Fisher announced a record-breaking financial result for the first quarter of 2010, thanks to double-digit sales growth in key product areas.

Fermentas International Frequently Asked Questions (FAQ)

  • When was Fermentas International founded?

    Fermentas International was founded in 1975.

  • Where is Fermentas International's headquarters?

    Fermentas International's headquarters is located at 830 Harrington Court, Burlington.

  • What is Fermentas International's latest funding round?

    Fermentas International's latest funding round is Acquired.

  • Who are the investors of Fermentas International?

    Investors of Fermentas International include Thermo Fisher Scientific, Summit Partners and Kenson Ventures.

  • Who are Fermentas International's competitors?

    Competitors of Fermentas International include Suneva Medical, HemoShear Therapeutics, Biodesix, Senseonics, Genetic Signatures and 10 more.

Compare Fermentas International to Competitors

EZ BioResearch

EZ BioResearch is a biotech company that focuses on developing, manufacturing and distributing molecular biology tool kits and laboratory consumable products.

Aironet Wireless Communications

BioArray is a molecular diagnostics company engaged in the development and commercialization of assay solutions for multiplexed analysis of DNA and protein markers using a customizable bead array ("BeadChip") format and automated assay delivery system, with available products for immunohematology, transplantation, genetic testing and immunology.

Expression Diagnostics

XDx is a molecular diagnostics company focused on the discovery, development and commercialization of non-invasive gene expression testing in the areas of transplant medicine and autoimmunity. Per the company, they have developed a proprietary method of utilizing gene expression in blood that aims to provide a new tool for physicians to manage the care of heart transplant patients. The molecular expression technology developed and implemented by XDx in heart transplant patient management is currently being explored to assist with other diseases that involve the immune system.


Mitomics, formerly Genesis Genomics, is developing molecular tests based on the mitochondrial genome in order to improve clinical insight and therapeutic decisions that affect patients worldwide. Leveraging its insights into the role of mitochondrial DNA (mtDNA), the company is developing a portfolio of molecular tests addressing significant unmet needs in oncology, including those related to prostate, breast, lung and skin cancers, and other disease states. The unique structural and functional characteristics of mtDNA make it a highly attractive system for biomarker discovery, early disease detection, monitoring, risk assessment and therapeutic targeting.


Knoesis seeks to develop bio-analytical hardware and reagents enabling cost-effective clinical diagnostics. The vision of the company is to allow everyone affordable access to rapid and specific diagnostic healthcare knowledge. Knoesis' first application is an immunosensor for the detection of latent tuberculosis infection.

Nanogen Adavanced Diagnostics S.r.l.

At Nanogen, Inc., the company develop diagnostic products that enable physicians to deliver improved patient care. The company's products allow faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These products include molecular diagnostic kits and reagents, and rapid test kits, which can be used in urgent care settings or at the point-of-care. Nanogen has pioneered developments in areas involving biomarkers, molecular biology and nanotechnology. The company's business focus is to bring better results to diagnostics and healthcare.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.